Tannic acid synergistically enhances the anticancer efficacy of cisplatin on liver cancer cells through mitochondria‑mediated apoptosis

Geng,Nana; Zheng,Xiang; Wu,Mingsong; Yang,Lei; Li,Xueying; Chen,Jindong

doi:10.3892/or.2019.7281

Tannic acid synergistically enhances the anticancer efficacy of cisplatin on liver cancer cells through mitochondria‑mediated apoptosis

Authors:
- Nana Geng
- Xiang Zheng
- Mingsong Wu
- Lei Yang
- Xueying Li
- Jindong Chen
View Affiliations

Affiliations: Special Key Laboratory of Oral Disease Research, Higher Education Institution in Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China, Department of Medical Genetics, Zunyi Medical University, Zunyi, Guizhou 563006, P.R. China
Published online on: August 16, 2019 https://doi.org/10.3892/or.2019.7281
Pages: 2108-2116

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (cis‑dichlorodiamine platinum, CDDP) is a potent antitumor agent. However, its clinical application is limited by its side effects and the development of drug resistance. Tannic acid (TA) has previously been reported to suppress tumor growth in different types of cancer. The present study evaluated the anticancer efficacy of TA in combination with CDDP on the liver cancer cell line HepG2, and investigated the associated underlying molecular mechanisms. The results revealed that treatment with TA or CDDP alone inhibited HepG2 cell growth, with a half maximal inhibitory concentration of 360 µM and 1.8 µg/ml, respectively. The combination of TA and CDDP induced mitochondria‑mediated apoptosis in HepG2 cells and significantly enhanced the growth inhibitory effect compared with TA or CDDP treatment alone. The results obtained from the present study suggest that the combination of TA and CDDP may exert synergistic anticancer effects and may be a novel adjuvant treatment for liver cancer.

View Figures

View References

1	Ferrin G, Aguilar-Melero P, Rodriguez-Peralvarez M, Montero-Alvarez JL and de la Mata M: Biomarkers for hepatocellular carcinoma: Diagnostic and therapeutic utility. Hepat Med. 7:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
2	Proença de Moraes T, Massignan B, Figueiredo AE, Barretti P, Olandoski M, Kirk A and Pecoits-Filho R: Systemic lupus erythematous and clinical outcomes in peritoneal dialysis. Lupus. 24:290–298. 2015. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
5	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gao H, Dong H, Li G and Jin H: Combined treatment with acetazolamide and cisplatin enhances chemosensitivity in laryngeal carcinoma Hep-2 cells. Oncol Lett. 15:9299–9306. 2018.PubMed/NCBI
7	Peng F, Zhang H, Du Y and Tan P: Cetuximab enhances cisplatin-induced endoplasmic reticulum stress-associated apoptosis in laryngeal squamous cell carcinoma cells by inhibiting expression of TXNDC5. Mol Med Rep. 17:4767–4776. 2018.PubMed/NCBI
8	Hoch MA, Cousins K, Nartey R, Riley K and Hartranft M: Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer. J Oncol Pharm Pract. 24:553–554. 2018. View Article : Google Scholar : PubMed/NCBI
9	Shen X, Gao X, Li H, Gu Y and Wang J: TIMP-3 increases the chemosensitivity of laryngeal carcinoma to cisplatin via facilitating mitochondria-dependent apoptosis. Oncol Res. 27:73–80. 2018. View Article : Google Scholar : PubMed/NCBI
10	Manohar S and Leung N: Cisplatin nephrotoxicity: A review of the literature. J Nephrol. 31:15–25. 2018. View Article : Google Scholar : PubMed/NCBI
11	Paken J, Govender CD, Pillay M and Sewram V: Cisplatin-associated ototoxicity: A review for the health professional. J Toxicol. 2016:18093942016. View Article : Google Scholar : PubMed/NCBI
12	Barabas K, Milner R, Lurie D and Adin C: Cisplatin: A review of toxicities and therapeutic applications. Vet Comp Oncol. 6:1–18. 2008. View Article : Google Scholar : PubMed/NCBI
13	Palmieri A, Iapichino A, Cura F, Scapoli L, Carinci F, Mandrone M and Martinelli M: Pre-treatment with berberine enhances effect of 5-fluorouracil and cisplatin in HEP2 laryngeal cancer cell line. J Biol Regul Homeost Agents. 32 (Suppl 1):S167–S177. 2018.
14	Matoba T, Ijichi K, Yanagi T, Kabaya K, Kawakita D, Beppu S, Torii J and Murakami S: Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma. Jpn J Clin Oncol. 47:1031–1037. 2017. View Article : Google Scholar : PubMed/NCBI
15	Lohitesh K, Chowdhury R and Mukherjee S: Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
16	Ryu SH and Chung YH: How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma. Liver Int. 30:496–498. 2010. View Article : Google Scholar : PubMed/NCBI
17	Sun Y, Zhang T, Wang B, Li H and Li P: Tannic acid, an inhibitor of poly(ADP-ribose) glycohydrolase, sensitizes ovarian carcinoma cells to cisplatin. Anticancer Drugs. 23:979–990. 2012.PubMed/NCBI
18	Booth BW, Inskeep BD, Shah H, Park JP, Hay EJ and Burg KJ: Tannic Acid preferentially targets estrogen receptor-positive breast cancer. Int J Breast Cancer. 2013:3696092013. View Article : Google Scholar : PubMed/NCBI
19	Tikoo K, Sane MS and Gupta C: Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anticancer activity: Potential role of tannins in cancer chemotherapy. Toxicol Appl Pharmacol. 251:191–200. 2011. View Article : Google Scholar : PubMed/NCBI
20	Cass CA and Burg KJ: Tannic acid cross-linked collagen scaffolds and their anticancer potential in a tissue engineered breast implant. J Biomater Sci Polym Ed. 23:281–298. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chen KS, Hsiao YC, Kuo DY, Chou MC, Chu SC, Hsieh YS and Lin TH: Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells. Leuk Res. 33:297–307. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cosan D, Soyocak A, Basaran A, Degirmenci I and Gunes HV: The effects of resveratrol and tannic acid on apoptosis in colon adenocarcinoma cell line. Saudi Med J. 30:191–195. 2009.PubMed/NCBI
23	Darvin P, Baeg SJ, Joung YH, Sp N, Kang DY, Byun HJ, Park JU and Yang YM: Tannic acid inhibits the Jak2/STAT3 pathway and induces G1/S arrest and mitochondrial apoptosis in YD-38 gingival cancer cells. Int J Oncol. 47:1111–1120. 2015. View Article : Google Scholar : PubMed/NCBI
24	Darvin P, Joung YH, Kang DY, Sp N, Byun HJ, Hwang TS, Sasidharakurup H, Lee CH, Cho KH, Park KD, et al: Tannic acid inhibits EGFR/STAT1/3 and enhances p38/STAT1 signalling axis in breast cancer cells. J Cell Mol Med. 21:720–734. 2017. View Article : Google Scholar : PubMed/NCBI
25	Kamei H, Koide T, Hashimoto Y, Kojima T and Hasegawa M: Tumor cell growth suppression by tannic acid. Cancer Biother Radiopharm. 14:135–138. 1999. View Article : Google Scholar : PubMed/NCBI
26	Karakurt S and Adali O: Tannic acid inhibits proliferation, migration, invasion of prostate cancer and modulates drug metabolizing and antioxidant enzymes. Anticancer Agents Med Chem. 16:781–789. 2016. View Article : Google Scholar : PubMed/NCBI
27	Majed F, Rashid S, Khan AQ, Nafees S, Ali N, Ali R, Khan R, Hasan SK, Mehdi SJ and Sultana S: Tannic acid mitigates the DMBA/croton oil-induced skin cancer progression in mice. Mol Cell Biochem. 399:217–228. 2015. View Article : Google Scholar : PubMed/NCBI
28	Nagesh PKB, Hatami E, Chowdhury P, Kashyap VK, Khan S, Hafeez BB, Chauhan SC, Jaggi M and Yallapu MM: Tannic acid induces endoplasmic reticulum stress-mediated apoptosis in prostate cancer. Cancers (Basel). 10:E682018. View Article : Google Scholar : PubMed/NCBI
29	Naus PJ, Henson R, Bleeker G, Wehbe H, Meng F and Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol. 46:222–229. 2007. View Article : Google Scholar : PubMed/NCBI
30	Ngobili TA, Shah H, Park JP, Kwist KW, Inskeep B, Burg KJ and Booth BW: Remodeling of tannic acid crosslinked collagen type I induces apoptosis in ER⁺ breast cancer cells. Anticancer Res. 35:1285–1290. 2015.PubMed/NCBI
31	Nie F, Liang Y, Jiang B, Li X, Xun H, He W, Lau HT and Ma X: Apoptotic effect of tannic acid on fatty acid synthase over-expressed human breast cancer cells. Tumour Biol. 37:2137–2143. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zhang J, Chen D, Han DM, Cheng YH, Dai C, Wu XJ, Che FY and Heng XY: Tannic acid mediated induction of apoptosis in human glioma Hs 683 cells. Oncol Lett. 15:6845–6850. 2018.PubMed/NCBI
33	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
34	Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 3:285–290. 1953.PubMed/NCBI
35	Estaquier J, Vallette F, Vayssiere JL and Mignotte B: The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 942:157–183. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zielińska-Przyjemska M, Kaczmarek M, Krajka-Kuźniak V, Łuczak M and Baer-Dubowska W: The effect of resveratrol, its naturally occurring derivatives and tannic acid on the induction of cell cycle arrest and apoptosis in rat C6 and human T98G glioma cell lines. Toxicol In Vitro. 43:69–75. 2017. View Article : Google Scholar : PubMed/NCBI